How Much Does Zepbound Cost in Mississippi in 2026?

Zepbound Retail Pricing Across Mississippi

The standard retail price for Zepbound in Mississippi is $1,059 per month, matching Eli Lilly's national list price. This figure applies across all five available dose strengths (2.5 mg, 5 mg, 7.5 mg, 10 mg, and 15 mg) and reflects four single-dose prefilled pens per 28-day supply. Prices are consistent whether you fill at a chain pharmacy in Jackson, a retail outlet in Gulfport, or an independent pharmacy in Tupelo.

Eli Lilly set this price point when the FDA approved Zepbound in November 2023 for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related condition such as type 2 diabetes, hypertension, or dyslipidemia. Unlike some specialty drugs with regional price variation, Zepbound's wholesale acquisition cost is uniform nationwide, so Mississippi pharmacies do not charge more or less than the national average.

A single month of Zepbound at list price totals $12,708 per year. For patients paying entirely out of pocket, this cost places the medication out of reach for most Mississippi households, where the median household income is among the lowest in the country. The gap between sticker price and actual patient cost depends heavily on insurance status, employer plan design, and whether a patient qualifies for manufacturer assistance.

Pharmacy markup is minimal. Most Mississippi retail pharmacies operate on thin margins for branded GLP-1 receptor agonist medications, so shopping between pharmacies rarely produces savings greater than $10 to $20 on cash-pay transactions.

Mississippi Medicaid Does Not Cover Zepbound

Mississippi's Medicaid program does not cover Zepbound for chronic weight management as of May 2026. This exclusion follows a pattern seen in the majority of state Medicaid programs, which classify anti-obesity medications as an optional benefit category rather than a mandatory one under federal Medicaid law.

The exclusion affects a significant portion of Mississippi's population. Approximately 780,000 Mississippians are enrolled in Medicaid or the Children's Health Insurance Program. Mississippi has not expanded Medicaid under the Affordable Care Act, which limits coverage to specific groups including pregnant women, children, the elderly, and individuals with disabilities who meet strict income thresholds. Adults without dependent children generally do not qualify for Mississippi Medicaid regardless of income.

For Medicaid-enrolled patients with type 2 diabetes, there may be an alternative pathway. Tirzepatide is also marketed as Mounjaro for glycemic control, and some state Medicaid programs cover Mounjaro under their diabetes formularies even when they exclude Zepbound for weight management. Mississippi's Division of Medicaid maintains a preferred drug list that is updated quarterly. Patients and prescribers should verify current formulary status through the Mississippi Division of Medicaid portal or by contacting the managed care organization administering their benefits.

The SURMOUNT-1 trial (N=2,539) demonstrated that tirzepatide 15 mg produced 22.5% mean body weight reduction at 72 weeks compared with 2.4% for placebo. These clinical results have intensified advocacy efforts for broader Medicaid coverage of GLP-1 receptor agonists across states, but budget constraints continue to drive coverage decisions in Mississippi.

Commercial Insurance Coverage in Mississippi

Private insurance coverage for Zepbound in Mississippi varies by plan, employer, and formulary tier. Large self-insured employers and plans offered through the Affordable Care Act marketplace each make independent coverage decisions.

Blue Cross Blue Shield of Mississippi, the state's dominant commercial insurer, maintains prior authorization requirements for GLP-1 receptor agonists prescribed for weight management. Approval typically requires documented BMI ≥30 (or ≥27 with a comorbidity), evidence of a failed dietary and exercise intervention lasting at least six months, and prescriber attestation that the patient does not have a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2.

When covered, Zepbound usually sits on a specialty or non-preferred brand tier, placing patient copays in the $75 to $250 per month range before any manufacturer assistance. Some plans impose step therapy, requiring documented trial and failure of an older agent such as phentermine or orlistat before approving tirzepatide.

The Endocrine Society's 2024 clinical practice guideline recommends pharmacotherapy as an adjunct to lifestyle modification for adults with BMI ≥30, or BMI ≥27 with complications. This guideline designation may support prior authorization appeals when initial requests are denied.

Mississippi state employees covered under the State and School Employees' Health Insurance Plan should check the plan's current formulary through the Mississippi Department of Finance and Administration, as formulary updates can shift Zepbound's coverage status mid-plan-year.

Eli Lilly Savings Card: How It Works in Mississippi

Eli Lilly offers a savings card program for Zepbound that can reduce out-of-pocket costs to $25 per month for eligible patients with commercial insurance. The program applies at the pharmacy counter and is accepted at virtually all Mississippi retail pharmacies that stock Zepbound.

Eligibility requires active commercial (private) insurance. Patients covered by Medicare, Medicaid, TRICARE, or any other federal or state government-funded program are not eligible. The savings card covers the difference between the patient's insurance copay and $25, up to a maximum annual benefit. Eli Lilly adjusts the annual cap periodically, so patients should verify the current limit at the Zepbound savings card portal.

For commercially insured patients whose plan does not cover Zepbound at all, Lilly has periodically offered a cash-pay savings program allowing self-pay patients to obtain a one-month supply for $399 to $549, depending on the active promotion. These programs are time-limited and subject to change. They do not apply at all pharmacy locations, and some require filling through Lilly's direct pharmacy channel.

The savings card activates automatically at participating pharmacies when the pharmacist processes the BIN and PCN numbers on the card alongside the patient's primary insurance. No mail-in rebates are required. Patients can register and download the card online, then present it at pickup.

One significant restriction: the savings card cannot be stacked with copay assistance from a separate third-party foundation. If a patient is receiving assistance from a 501(c)(3) copay foundation, the Lilly card terms may prohibit concurrent use.

Compounded Tirzepatide in Mississippi

Compounded tirzepatide is available in Mississippi through licensed 503A compounding pharmacies at approximately $249 per month. This represents a 76% reduction compared with brand-name Zepbound's list price.

A 503A pharmacy operates under Section 503A of the Federal Food, Drug, and Cosmetic Act, compounding medications based on individual patient prescriptions. Mississippi's Board of Pharmacy regulates these pharmacies and requires them to hold a valid compounding license. The Mississippi State Board of Pharmacy conducts inspections and enforces compliance with USP <797> sterile compounding standards.

The legal status of compounded tirzepatide depends on FDA shortage designations. While tirzepatide remains on the FDA drug shortage list, 503A and 503B pharmacies may compound copies of the commercially available drug. If and when the FDA removes tirzepatide from the shortage list, the legal basis for compounding shifts significantly, and 503A pharmacies may no longer be permitted to compound tirzepatide unless they meet a specific patient-need exemption.

Patients considering compounded tirzepatide should confirm three things with their pharmacy: the source of the active pharmaceutical ingredient (it should come from an FDA-registered outsourcing facility or supplier), the pharmacy's state compounding license status, and whether the pharmacy conducts third-party potency and sterility testing on each batch. The FDA's compounding quality page provides current regulatory guidance.

Dr. Caroline Apovian, co-director of the Center for Weight Management and Wellness at Brigham and Women's Hospital, has noted: "Patients choosing compounded GLP-1 medications should ensure their pharmacy follows cGMP-equivalent standards. The cost savings are real, but quality assurance cannot be optional when injecting a peptide subcutaneously."

Pricing for compounded tirzepatide in Mississippi varies by dose. Starting doses (2.5 mg weekly) may cost less than maintenance doses (10 mg or 15 mg weekly) because the active ingredient quantity per vial increases proportionally.

Telehealth Access to Zepbound in Mississippi

Mississippi permits telehealth prescribing of Zepbound. State law allows providers licensed in Mississippi to prescribe controlled and non-controlled medications through audio-visual telehealth encounters, and several national telehealth platforms now serve Mississippi patients seeking GLP-1 receptor agonist prescriptions.

The Mississippi State Board of Medical Licensure requires that prescribers conducting telehealth visits hold an active Mississippi medical license or practice under a multistate compact agreement. Nurse practitioners in Mississippi have full practice authority, meaning they can prescribe Zepbound independently without physician oversight.

A typical telehealth pathway for obtaining Zepbound in Mississippi involves an initial video consultation (15 to 30 minutes), during which the provider reviews BMI, weight history, comorbidities, and contraindications. If the patient meets FDA-label criteria for Zepbound, the provider sends the prescription electronically to the patient's preferred pharmacy.

Telehealth visits for weight management in Mississippi typically cost between $99 and $199 for the initial consultation and $49 to $99 for monthly follow-ups. Some telehealth platforms bundle the visit cost with the medication when dispensing compounded tirzepatide through a partner pharmacy.

Patients in rural Mississippi communities, where obesity rates exceed 40% in several counties according to CDC prevalence data, may find telehealth especially valuable given limited access to endocrinologists and obesity medicine specialists. Mississippi has fewer than 30 board-certified obesity medicine physicians statewide.

Discount Programs and Patient Assistance

Beyond the Lilly savings card, several pathways can reduce Zepbound costs for Mississippi patients.

Eli Lilly's Zepbound Patient Assistance Program provides medication at no cost to uninsured patients who meet income requirements (generally household income at or below 400% of the federal poverty level). Applications require documentation of income and a prescriber's signature. Processing takes two to four weeks.

Pharmacy discount platforms such as GoodRx and RxSaver display negotiated cash prices at Mississippi pharmacies. These prices fluctuate but occasionally dip below the $1,059 list price by $50 to $100 at select locations. These discount cards are not insurance and cannot be combined with the Lilly savings card or insurance copays.

The American Diabetes Association provides a resource directory for patients struggling with medication costs, including referrals to state and national patient assistance programs.

For Mississippi patients willing to consider therapeutic alternatives, semaglutide 2.4 mg (Wegovy) produced 14.9% mean weight loss at 68 weeks in STEP-1 (N=1,961) and may have different coverage status on some Mississippi insurance formularies. The SURMOUNT-1 trial showed tirzepatide's weight loss exceeded that of semaglutide in an indirect comparison (22.5% vs. 14.9%), though no head-to-head trial between Zepbound and Wegovy has been completed.

Mississippi patients with type 2 diabetes and obesity may find it easier to obtain insurance coverage for Mounjaro (tirzepatide's diabetes-indication brand) than for Zepbound, since many formularies include GLP-1 agonists for glycemic control but exclude them for weight management alone.

Clinical Efficacy Supporting the Investment

The SURMOUNT clinical trial program provides the evidence base justifying Zepbound's price tag for patients evaluating whether to pursue coverage or pay out of pocket.

In SURMOUNT-1, participants receiving tirzepatide 15 mg lost a mean of 22.5% of body weight at 72 weeks. The 10 mg dose produced 21.4% weight loss, and the 5 mg dose produced 16.0%, all versus 2.4% for placebo (P<0.001 for all comparisons). Ninety-six percent of participants on tirzepatide 10 mg or 15 mg achieved at least 5% weight loss, and over half the participants on the highest dose lost more than 20% of their starting weight.

"The magnitude of weight reduction with tirzepatide approaches what we previously saw only with bariatric surgery," said Dr. Ania Jastreboff, lead investigator of SURMOUNT-1 and director of the Yale Obesity Research Center. "This redefines what is pharmacologically achievable."

SURMOUNT-2, published in The Lancet, evaluated tirzepatide specifically in adults with type 2 diabetes and obesity (N=938). Participants on tirzepatide 15 mg lost 14.7% of body weight and achieved a 2.1 percentage-point reduction in HbA1c at 72 weeks. These dual benefits on both weight and glucose make tirzepatide particularly cost-effective for patients with overlapping diagnoses.

The most common adverse events across the SURMOUNT program were gastrointestinal: nausea (affecting 24% to 33% of participants at higher doses), diarrhea, and constipation. These effects were most pronounced during the dose-titration phase and diminished over time in the majority of participants.

Making the Financial Decision

For a Mississippi resident weighing Zepbound's cost against its clinical benefit, the decision tree branches along insurance status.

Commercially insured with coverage: apply for the Lilly savings card, pay approximately $25 per month, and work with your prescriber to complete prior authorization paperwork proactively. Attach the Endocrine Society guideline recommendation and SURMOUNT-1 data to the prior authorization submission.

Commercially insured without coverage: file a formulary exception request citing medical necessity, BMI documentation, and prior lifestyle intervention. If denied, appeal with a peer-to-peer review. During the appeals process, consider the Lilly cash-pay program or compounded tirzepatide at $249 per month to avoid treatment interruption.

Uninsured: apply to Lilly's patient assistance program. If income exceeds the threshold, compounded tirzepatide through a licensed Mississippi 503A pharmacy at $249 per month is the most cost-effective option with verified active ingredient.

Medicaid-enrolled: explore whether Mounjaro (diabetes indication) is covered under your specific managed care plan if you have a concurrent type 2 diabetes diagnosis. If not, compounded tirzepatide or patient assistance may be the remaining options.

Mississippi patients starting Zepbound should expect to begin at the 2.5 mg dose for four weeks, then titrate upward in 2.5 mg increments every four weeks until reaching the maintenance dose their provider selects (typically 10 mg or 15 mg weekly based on tolerability and response).